The Active Surveillance Study

RecruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

August 22, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Prostate Cancer
Interventions
OTHER

Active Surveillance

"Active surveillance (AS) is an accepted management strategy for men diagnosed with low risk PrCa, generally defined as PSA \<10ng/ml and Gleason score of ≤6 and clinical stage T1 to T2a. Occasionally, a minority of men with Gleason 3+4 disease are included, though majority of those included in AS studies have Gleason 3+3 disease or less.~Men in AS studies have repeated biopsies based on various criteria including PSA velocity, repeat biopsy at set time points and change noted on digital rectal examination (DRE), biopsy or MRI imaging. Progression of disease has been defined in various ways in different studies, generally, using criteria of Gleason upgrade to greater than Gleason 3+3, evidence of Gleason 4 or Gleason 5 disease, \>50% involvement of any one biopsy core, and greater than 2 cores positive on repeat biopsy. Percentages of men on AS who have upgrade on repeat biopsy have been found to be 19-34%; this may differ in our cohort of men with increased genetic risk for PrCa."

Trial Locations (1)

SM2 5PT

RECRUITING

Institute of Cancer Research and Royal Marsden Hospital, Sutton

All Listed Sponsors
collaborator

Royal Marsden NHS Foundation Trust

OTHER

lead

Institute of Cancer Research, United Kingdom

OTHER